Bristol-Myers SquibbBMY
BMY
About: Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Employees: 34,100
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
102% more first-time investments, than exits
New positions opened: 266 | Existing positions closed: 132
44% more funds holding in top 10
Funds holding in top 10: 18 [Q2] → 26 (+8) [Q3]
21% more capital invested
Capital invested by funds: $67.9B [Q2] → $82.1B (+$14.2B) [Q3]
5% more funds holding
Funds holding: 2,109 [Q2] → 2,212 (+103) [Q3]
5% less call options, than puts
Call options by funds: $1.9B | Put options by funds: $2B
2.22% less ownership
Funds ownership: 80.6% [Q2] → 78.38% (-2.22%) [Q3]
11% less repeat investments, than reductions
Existing positions increased: 802 | Existing positions reduced: 904
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$39
31%
downside
Avg. target
$62
9%
upside
High target
$73
30%
upside
7 analyst ratings
3 positive
43%
3 neutral
43%
1 negative
14%
Truist Securities Robyn Karnauskas 11% 1-year accuracy 3 / 28 met price target | 15%upside $65 | Buy Maintained | 8 Jan 2025 |
Jefferies Akash Tewari 8% 1-year accuracy 1 / 13 met price target | 24%upside $70 | Buy Upgraded | 16 Dec 2024 |
B of A Securities Tim Anderson 67% 1-year accuracy 4 / 6 met price target | 12%upside $63 | Neutral Reinstated | 10 Dec 2024 |
Citigroup Andrew Baum 25% 1-year accuracy 1 / 4 met price target | 7%upside $60 | Neutral Maintained | 12 Nov 2024 |
BMO Capital Evan Seigerman 44% 1-year accuracy 7 / 16 met price target | 8%upside $61 | Market Perform Maintained | 12 Nov 2024 |
Financial journalist opinion
Based on 29 articles about BMY published over the past 30 days
Positive
Seeking Alpha
1 day ago
Top 4 Immunology Stocks Poised For Growth In 2025
This article will reveal an in-depth analysis of drugs being developed to combat immunological disorders. Big Pharma is keenly interested in the global immunology drugs market, which is anticipated to exceed $190 billion by 2028. Every year, regulatory agencies approve dozens of biosimilars and brand-name drugs, so Seeking Alpha readers should be careful when making decisions.
Neutral
Zacks Investment Research
3 days ago
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
The latest trading day saw Bristol Myers Squibb (BMY) settling at $56.29, representing a -0.16% change from its previous close.
Positive
CNBC
5 days ago
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in sales across different uses. Company executives said each treatment type they are studying has multibillion dollar potential, including Alzheimer's disease psychosis, agitation and cognition, along with bipolar disease and autism.
Positive
Zacks Investment Research
6 days ago
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Positive
CNBC Television
1 week ago
Feedback on schizophrenia treatment has been great, says Bristol Myers Squibb CEO
Bristol Myers Squibb CEO Christopher Boerner joins 'Mad Money' host Jim Cramer to talk its new schizophrenia treatment Cobenfy, its oncology business, and more.
Neutral
Seeking Alpha
1 week ago
Bristol-Myers Squibb Company (BMY) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY ) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2024 10:30 AM ET Company Participants Chris Boerner - Chairman and Chief Executive Officer Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning everybody.
Neutral
GlobeNewsWire
1 week ago
ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors
ArsenalBio and Bristol Myers Squibb achieve milestone for AB-4000 series as part of a multi-program collaboration to advance next-gen T cell therapies.
Positive
24/7 Wall Street
1 week ago
Look Out, Interest Rate Cuts Could Be Over: Buy These High-Yield Passive Income Stars Now
When the Federal Reserve met in December, it threw the stock market and Wall Street a pretty big curveball when it revealed that the dot plot for interest rate cuts for 2025 had been lowered to just two cuts.
Negative
Zacks Investment Research
1 week ago
Bristol Myers Squibb (BMY) Stock Slides as Market Rises: Facts to Know Before You Trade
Bristol Myers Squibb (BMY) concluded the recent trading session at $56.81, signifying a -0.58% move from its prior day's close.
Positive
Seeking Alpha
1 week ago
Buy 6 'Safer' Dividend Dogs Of 23 January Barron's Better Bets Than T-Bills
Seven of the ten lowest-priced BBB Dogs, including Altria, Pfizer, and Verizon, are ready to buy, with dividends from $1K invested exceeding single share prices. Analysts project 16.27% to 32.98% net gains by January 2026 for the top-ten BBB Dogs, with LyondellBasell leading at 32.98%. Six of the top ten BBB Dogs are ideally priced, with dividends from $1K invested exceeding single share prices, meeting the dogcatcher ideal.
Charts implemented using Lightweight Charts™